316 related articles for article (PubMed ID: 35377706)
1. Effects of Empagliflozin on Symptoms, Physical Limitations, and Quality of Life in Patients Hospitalized for Acute Heart Failure: Results From the EMPULSE Trial.
Kosiborod MN; Angermann CE; Collins SP; Teerlink JR; Ponikowski P; Biegus J; Comin-Colet J; Ferreira JP; Mentz RJ; Nassif ME; Psotka MA; Tromp J; Brueckmann M; Blatchford JP; Salsali A; Voors AA
Circulation; 2022 Jul; 146(4):279-288. PubMed ID: 35377706
[TBL] [Abstract][Full Text] [Related]
2. Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction: Results From the DAPA-HF Trial.
Kosiborod MN; Jhund PS; Docherty KF; Diez M; Petrie MC; Verma S; Nicolau JC; Merkely B; Kitakaze M; DeMets DL; Inzucchi SE; Køber L; Martinez FA; Ponikowski P; Sabatine MS; Solomon SD; Bengtsson O; Lindholm D; Niklasson A; Sjöstrand M; Langkilde AM; McMurray JJV
Circulation; 2020 Jan; 141(2):90-99. PubMed ID: 31736335
[TBL] [Abstract][Full Text] [Related]
3. Empagliflozin, Health Status, and Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial.
Butler J; Filippatos G; Jamal Siddiqi T; Brueckmann M; Böhm M; Chopra VK; Pedro Ferreira J; Januzzi JL; Kaul S; Piña IL; Ponikowski P; Shah SJ; Senni M; Vedin O; Verma S; Peil B; Pocock SJ; Zannad F; Packer M; Anker SD
Circulation; 2022 Jan; 145(3):184-193. PubMed ID: 34779658
[TBL] [Abstract][Full Text] [Related]
4. Effects of Semaglutide on Symptoms, Function, and Quality of Life in Patients With Heart Failure With Preserved Ejection Fraction and Obesity: A Prespecified Analysis of the STEP-HFpEF Trial.
Kosiborod MN; Verma S; Borlaug BA; Butler J; Davies MJ; Jon Jensen T; Rasmussen S; Erlang Marstrand P; Petrie MC; Shah SJ; Ito H; Schou M; Melenovský V; Abhayaratna W; Kitzman DW;
Circulation; 2024 Jan; 149(3):204-216. PubMed ID: 37952180
[TBL] [Abstract][Full Text] [Related]
5. Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial.
Butler J; Anker SD; Filippatos G; Khan MS; Ferreira JP; Pocock SJ; Giannetti N; Januzzi JL; Piña IL; Lam CSP; Ponikowski P; Sattar N; Verma S; Brueckmann M; Jamal W; Vedin O; Peil B; Zeller C; Zannad F; Packer M;
Eur Heart J; 2021 Mar; 42(13):1203-1212. PubMed ID: 33420498
[TBL] [Abstract][Full Text] [Related]
6. Effect of Dapagliflozin Versus Placebo on Symptoms and 6-Minute Walk Distance in Patients With Heart Failure: The DETERMINE Randomized Clinical Trials.
McMurray JJV; Docherty KF; de Boer RA; Hammarstedt A; Kitzman DW; Kosiborod MN; Maria Langkilde A; Reicher B; Senni M; Shah SJ; Wilderäng U; Verma S; Solomon SD
Circulation; 2024 Mar; 149(11):825-838. PubMed ID: 38059368
[TBL] [Abstract][Full Text] [Related]
7. Effect of Dapagliflozin on Health Status in Patients With Preserved or Mildly Reduced Ejection Fraction.
Kosiborod MN; Bhatt AS; Claggett BL; Vaduganathan M; Kulac IJ; Lam CSP; Hernandez AF; Martinez FA; Inzucchi SE; Shah SJ; de Boer RA; Jhund PS; Desai AS; Fang JC; Han Y; Comin-Colet J; Vardeny O; Lindholm D; Wilderäng U; Bengtsson O; McMurray JJV; Solomon SD
J Am Coll Cardiol; 2023 Feb; 81(5):460-473. PubMed ID: 36526515
[TBL] [Abstract][Full Text] [Related]
8. Treatment effects of empagliflozin in hospitalized heart failure patients across the range of left ventricular ejection fraction - Results from the EMPULSE trial.
Tromp J; Kosiborod MN; Angermann CE; Collins SP; Teerlink JR; Ponikowski P; Biegus J; Ferreira JP; Nassif ME; Psotka MA; Brueckmann M; Blatchford JP; Steubl D; Voors AA
Eur J Heart Fail; 2024 Apr; 26(4):963-970. PubMed ID: 38572654
[TBL] [Abstract][Full Text] [Related]
9. The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial.
Nassif ME; Windsor SL; Borlaug BA; Kitzman DW; Shah SJ; Tang F; Khariton Y; Malik AO; Khumri T; Umpierrez G; Lamba S; Sharma K; Khan SS; Chandra L; Gordon RA; Ryan JJ; Chaudhry SP; Joseph SM; Chow CH; Kanwar MK; Pursley M; Siraj ES; Lewis GD; Clemson BS; Fong M; Kosiborod MN
Nat Med; 2021 Nov; 27(11):1954-1960. PubMed ID: 34711976
[TBL] [Abstract][Full Text] [Related]
10. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial.
Voors AA; Angermann CE; Teerlink JR; Collins SP; Kosiborod M; Biegus J; Ferreira JP; Nassif ME; Psotka MA; Tromp J; Borleffs CJW; Ma C; Comin-Colet J; Fu M; Janssens SP; Kiss RG; Mentz RJ; Sakata Y; Schirmer H; Schou M; Schulze PC; Spinarova L; Volterrani M; Wranicz JK; Zeymer U; Zieroth S; Brueckmann M; Blatchford JP; Salsali A; Ponikowski P
Nat Med; 2022 Mar; 28(3):568-574. PubMed ID: 35228754
[TBL] [Abstract][Full Text] [Related]
11. Sodium-glucose co-transporter 2 inhibition in patients hospitalized for acute decompensated heart failure: rationale for and design of the EMPULSE trial.
Tromp J; Ponikowski P; Salsali A; Angermann CE; Biegus J; Blatchford J; Collins SP; Ferreira JP; Grauer C; Kosiborod M; Nassif ME; Psotka MA; Brueckmann M; Teerlink JR; Voors AA
Eur J Heart Fail; 2021 May; 23(5):826-834. PubMed ID: 33609072
[TBL] [Abstract][Full Text] [Related]
12. Effect of dapagliflozin on health status and quality of life across the spectrum of ejection fraction: Participant-level pooled analysis from the DAPA-HF and DELIVER trials.
Bhatt AS; Kosiborod MN; Vaduganathan M; Claggett BL; Miao ZM; Kulac IJ; Lam CSP; Hernandez AF; Martinez F; Inzucchi SE; Shah SJ; de Boer RA; Jhund PS; Desai AS; Petersson M; Langkilde AM; McMurray JJV; Solomon SD
Eur J Heart Fail; 2023 Jul; 25(7):981-988. PubMed ID: 37211977
[TBL] [Abstract][Full Text] [Related]
13. Effect of Torsemide Versus Furosemide on Symptoms and Quality of Life Among Patients Hospitalized for Heart Failure: The TRANSFORM-HF Randomized Clinical Trial.
Greene SJ; Velazquez EJ; Anstrom KJ; Clare RM; DeWald TA; Psotka MA; Ambrosy AP; Stevens GR; Rommel JJ; Alexy T; Ketema F; Kim DY; Desvigne-Nickens P; Pitt B; Eisenstein EL; Mentz RJ;
Circulation; 2023 Jul; 148(2):124-134. PubMed ID: 37212600
[TBL] [Abstract][Full Text] [Related]
14. Impact of empagliflozin on decongestion in acute heart failure: the EMPULSE trial.
Biegus J; Voors AA; Collins SP; Kosiborod MN; Teerlink JR; Angermann CE; Tromp J; Ferreira JP; Nassif ME; Psotka MA; Brueckmann M; Salsali A; Blatchford JP; Ponikowski P
Eur Heart J; 2023 Jan; 44(1):41-50. PubMed ID: 36254693
[TBL] [Abstract][Full Text] [Related]
15. Dapagliflozin Improves Heart Failure Symptoms and Physical Limitations Across the Full Range of Ejection Fraction: Pooled Patient-Level Analysis From DEFINE-HF and PRESERVED-HF Trials.
Nassif ME; Windsor SL; Gosch K; Borlaug BA; Husain M; Inzucchi SE; Kitzman DW; McGuire DK; Pitt B; Scirica BM; Shah SJ; Umpierrez G; Austin BA; Lamba S; Khumri T; Sharma K; Kosiborod MN
Circ Heart Fail; 2023 Jul; 16(7):e009837. PubMed ID: 37203441
[TBL] [Abstract][Full Text] [Related]
16. Vericiguat and Health-Related Quality of Life in Patients With Heart Failure With Reduced Ejection Fraction: Insights From the VICTORIA Trial.
Butler J; Stebbins A; Melenovský V; Sweitzer NK; Cowie MR; Stehlik J; Khan MS; Blaustein RO; Ezekowitz JA; Hernandez AF; Lam CSP; Nkulikiyinka R; O'Connor CM; Pieske BM; Ponikowski P; Spertus JA; Voors AA; Anstrom KJ; Armstrong PW;
Circ Heart Fail; 2022 Jun; 15(6):e009337. PubMed ID: 35656822
[TBL] [Abstract][Full Text] [Related]
17. Mineralocorticoid receptor antagonist use and the effects of empagliflozin on clinical outcomes in patients admitted for acute heart failure: Findings from EMPULSE.
Ferreira JP; Blatchford JP; Teerlink JR; Kosiborod MN; Angermann CE; Biegus J; Collins SP; Tromp J; Nassif ME; Psotka MA; Comin-Colet J; Mentz RJ; Brueckmann M; Nordaby M; Ponikowski P; Voors AA
Eur J Heart Fail; 2023 Oct; 25(10):1797-1805. PubMed ID: 37540060
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of empagliflozin in heart failure with preserved ejection fraction according to frailty status in EMPEROR-Preserved.
Coats AJS; Butler J; Tsutsui H; Doehner W; Filippatos G; Ferreira JP; Böhm M; Chopra VK; Verma S; Nordaby M; Iwata T; Nitta D; Ponikowski P; Zannad F; Packer M; Anker SD
J Cachexia Sarcopenia Muscle; 2024 Feb; 15(1):412-424. PubMed ID: 38158636
[TBL] [Abstract][Full Text] [Related]
19. Health status across major subgroups of patients with heart failure and preserved ejection fraction.
Siddiqi TJ; Anker SD; Filippatos G; Ferreira JP; Pocock SJ; Böhm M; Brueckmann M; Chopra VK; Iwata T; Januzzi J; Piña IL; Ponikowski P; Senni M; Vedin O; Verma S; Zhang Y; Zannad F; Packer M; Butler J
Eur J Heart Fail; 2023 Sep; 25(9):1623-1631. PubMed ID: 36974746
[TBL] [Abstract][Full Text] [Related]
20. The win ratio method in heart failure trials: lessons learnt from EMPULSE.
Pocock SJ; Ferreira JP; Collier TJ; Angermann CE; Biegus J; Collins SP; Kosiborod M; Nassif ME; Ponikowski P; Psotka MA; Teerlink JR; Tromp J; Gregson J; Blatchford JP; Zeller C; Voors AA
Eur J Heart Fail; 2023 May; 25(5):632-641. PubMed ID: 37038330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
